During the war in Bosnia and Herzegovina from1992 to 1995, tens of thousands of refugees came to the United States. In this story narrated by Anna Rice, Dino Jahic reports they brought some unique culinary traditions to the U.S.
…
Dawn Wells, who parlayed her girl-next-door charm and wholesome beauty into enduring TV fame as the sweet-natured desert island castaway Mary Ann on the classic 1960s sitcom Gilligan’s Island, died Wednesday at age 82, her publicist said.
Wells, who won the title of Miss Nevada in 1959 and competed in the Miss America contest, died from complications of COVID-19, publicist Harlan Boll said in a statement.
Born in the gambling city of Reno, Wells played Kansas farm girl Mary Ann Summers, one of seven castaways stranded after their boat, the S.S. Minnow, became battered in a storm during what was supposed to be a three-hour tour from Hawaii. Wells beat out actors including Raquel Welch for her role.
Gilligan’s Island ran for three seasons (1964-1967) with a cast that also included Bob Denver as the zany Gilligan, Alan Hale Jr. as the Skipper, Jim Backus as millionaire Thurston Howell III, Natalie Schafer as his posh wife, Russell Johnson as the Professor and Tina Louise as movie star Ginger.The death of Wells leaves Louise, 86, the sole survivor of these cast members. FILE – In this 1965 file photo, Dawn Wells, center, poses with fellow cast members of “Gilligan’s Island,” Bob Denver and Alan Hale Jr., in Los Angeles.The 98 episodes invariably involved their efforts in vain to get off the island, even as a parade of guest stars dropped in and had no trouble getting out. The show drew the wrath of critics, but its innocent fun caught on with viewers at a time of tumult in America after the assassination of a president and during the rise of the Civil Rights Movement and the escalation of the Vietnam War. Wells, playing a cheerful brunette Midwestern farm girl, appeared in the series wearing short shorts, midriff tops and pigtails. Louise, playing a buxom red-haired sensation akin to Marilyn Monroe, wore slinky, form-fitting dresses. The two inspired what became an enduring pop culture question for men: “Ginger or Mary Ann?”
Wells said that question was the most common topic mentioned to her by fans. “Mostly they’ll pick a favorite, Ginger or Mary Ann. For some reason, they feel they have to make a choice,” Wells told Forbes magazine in 2016.
Wells had effusive praise for Denver and her other cast mates but was not especially close to Louise, who distanced herself from the Ginger character and declined to appear in various Gilligan’s Island reboots with her former co-stars.
“We had nothing against each other,” Wells told the Los Angeles Times in 2014. “We didn’t have much in common.”
Gilligan’s Island was canceled by network executives despite respectable ratings, then became ubiquitous in syndicated reruns.
“A misconception is that we must be wealthy, rolling in the dough, because we got residuals. We didn’t really get a dime,” Wells told Forbes.
Wells said she was paid $750 a week, adding, “Sherwood Schwartz, our producer, reportedly made $90 million on the reruns alone.”
Like some of her co-stars, she suffered from typecasting in Hollywood in the years after the series ended, appearing in TV guest spots and stage work before taking roles in B-movies.
FILE – This Oct. 2, 1978, photo shows the cast of “Gilligan’s Island,” from left, Russell Johnson, Jim Backus, Natalie Schafer, Alan Hale Jr., Bob Denver, Judith Baldwin replacing original cast member Tina Louise, and Dawn Wells.In light of the show’s steady popularity in the 1970s, three made-for-TV movies were made with progressively far-fetched plots involving Soviet satellites and visiting basketball players: Rescue from Gilligan’s Island (1978), The Castaways on Gilligan’s Island (1979) and The Harlem Globetrotters on Gilligan’s Island (1981).
Wells also lent her voice to the animated Gilligan’s Planet (1982) in which the castaways become stranded on a faraway planet.
Wells also capitalized on her fame by writing, Mary Ann’s Gilligan’s Island Cookbook, and later, for the 50th anniversary of the series in 2014, the book, What Would Mary Ann Do? A Guide to Life.
Wells was born Oct. 18, 1938, in Reno, studied theater at the University of Washington, and headed to Hollywood after her beauty pageant success.
She embraced her pop culture status but said there was more to her than just being Mary Ann.
“I’m deeper, smarter, more ambitious, funnier. I think if you meet me for 15 minutes, there is nothing you won’t know: what you see is what you get,” she told Forbes.
…
Britain approved another vaccine for the coronavirus Wednesday, this one developed by Oxford University and the pharmaceutical firm AstraZeneca. As Henry Ridgwell reports from London, scientists say the vaccine could be a game changer in the global fight against the pandemic.Camera: Henry Ridgwell Produced by: Henry Hernandez
…
The year 2020 is ending with good news about two more potential vaccines that could slowly bring an end to the global COVID-19 pandemic that has killed nearly 1.8 million people out of a total of nearly 82 million infections. Britain’s medical regulatory agency announced Wednesday that it has granted emergency authorization of a coronavirus vaccine developed jointly by British-Swedish pharmaceutical giant AstraZeneca and Oxford University. Late-stage clinical trials of the AstraZeneca-Oxford vaccine revealed it to be 70% effective against COVID-19. The vaccine had a 62% efficacy rate for participants given a full two doses, but tests of a smaller sub-group revealed it to be 90% effective when given a half-dose followed by a full dose weeks later. The AstraZeneca/Oxford vaccine is the second to be approved by Britain for its mass inoculation effort, which began earlier this month with the vaccine developed by U.S.-based Pfizer and Germany’s BioNTech. The new vaccine will be distributed across the country within days, with Britain having already ordered 100 million doses. Unlike the Pfizer-BioNTech vaccine, which needs to be stored in super-cold refrigerators at temperatures below 70 degrees Celsius, the newly approved vaccine can be stored at normal temperatures of 2 to 8 degrees Celsius, making it easier to transport and administer to people in poorer and remote nations. But the AstraZeneca-Oxford vaccine has come under intense scrutiny over the number of people who took part in the smaller sub-group, which was just 2,741, and whether it is effective for people over age 55. In a related development, Chinese state-owned drug maker Sinopharm is seeking regulatory approval for its COVID-19 vaccine after it was found to be 79.3 percent effective against the disease in a final large-scale clinical trial. The vaccine, developed by Sinopharm’s subsidiary Beijing Biological Products Institute, is one of five vaccines developed by Chinese companies that have already been administered to more than one million people in China under its emergency use program while still undergoing Phase 3 clinical trials. The United Arab Emirates granted emergency use approval for a Sinopharm-developed vaccine earlier this month after it was shown to be 86% effective in preventing moderate and severe cases of the virus in a late-stage clinical trial back in September. Wednesday’s vaccine news comes just days after several European Union countries began inoculating its citizens after receiving a first shipment of 10,000 doses of the Pfizer-BioNTech vaccine. Vaccinations also began Wednesday in Singapore, with a 46-year-old nurse the first in the city-state to be inoculated with the Pfizer-BioNTech vaccine. The nurse is one of more than 30 staffers at the National Centre for Infectious Diseases to receive the first dose of two-shot vaccine, with the second dose to be delivered sometime in January. Singapore, which has one of the lowest rates of total infections with just 58,569, including 29 deaths, is the first Asian nation to approve the Pfizer-BioNTech vaccine. It expects to have enough vaccine doses for all its 5.7 million people by the third quarter of 2021. Meanwhile, another potential COVID-19 vaccine developed by U.S.-based drug maker Novavax has begun final-stage testing in the United States. The trials involving 30,000 volunteers will focus on high-risk older adults, as well as people from Black and Hispanic communities who have been disproportionately affected by the virus.
…
